Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere Trivalent Influenza Vaccine is associated with adverse events
Steve Rockman, Allison Dyson, Sandra Koernig, Dorit Becher, Milica Ng, Adriana Baz Morelli, Megan Barnden, Mimi LK Tang, Martin Pearse, Eugene Maraskovsky
Vaccine | ELSEVIER SCI LTD | Published : 2014
In Australia, during the 2010 Southern Hemisphere (SH) influenza season, there was an unexpected increase in post-marketing adverse event reports of febrile seizures (FS) in children under 5 years of age shortly after vaccination with the CSL trivalent influenza vaccine (CSL 2010 SH TIV) compared to previous CSL TIVs and other licensed 2010 SH TIVs. The present study describes the outcomes of a series of in vitro experiments directed at elucidating the root cause. The scientific investigations found that a subset of paediatric donors displayed elevated cytokine/chemokine responses to the CSL 2010 SH TIV but not to previous CSL TIVs nor other 2010 SH TIVs. The induction of elevated cytokines/..View full abstract
Steve Rockman is an employee of bioCSL; Allison Dyson, Sandra Koernig, Dorit Becher, Milica Ng, Adriana Baz Morelli, Megan Barnden, Martin Pearse and Eugene Maraskovslcy are employees of CSL Limited whose product was studied in the present work. Mimi Tang is Chairman of the Asia Pacific Immunoglobulins in Immunology Expert Group (APIIEG), which has been supported by CSL Limited.